Welcome to our dedicated page for Galera Therapeutics SEC filings (Ticker: GRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Galera Therapeutics filings document a clinical-stage oncology company’s material agreements, governance matters, capital structure and operating disclosures. The company’s SEC reports include 8-K events for asset transactions involving dismutase mimetics, amendments to preferred-stock terms, conversions of Series B Non-Voting Convertible Preferred Stock, pre-funded warrant exercises, and executive compensation arrangements.
Galera’s proxy and annual-meeting materials cover stockholder voting procedures, director nominations, governance requirements and related capital-structure disclosures. Its public-company records also identify GRTX common stock on the OTCQB Market and provide formal disclosure of financial results, reporting obligations, risk-related matters and corporate actions affecting the company’s oncology development business.
Galera Therapeutics, Inc. converted 76,479.175 shares of its Series B Non-Voting Convertible Preferred Stock into 76,479,164 shares of common stock on April 7, 2026, under the existing Certificate of Designation. Fractional common shares will be settled in cash based on the trading value at the conversion date.
After this partial mandatory conversion, 42,839.11 shares of Series B Preferred Stock remain outstanding. On April 8, 2026, affiliates of Ikarian Capital, LLC exercised pre-funded warrants for 8,488,229 common shares at an exercise price of $0.001 per share, providing approximately $8,488.23 to the company, with warrants for an additional 14,552,811 common shares still outstanding.
Galera Therapeutics, Inc. has scheduled its Combined 2025 and 2026 Annual Meeting of Stockholders for May 8, 2026. Because this date is more than 60 days after the prior Annual Meeting held on February 24, 2025, the company is updating key stockholder proposal and nomination deadlines.
Stockholders seeking to nominate directors or present other business under the company’s Amended and Restated Bylaws must deliver notice to the secretary at the principal executive office by April 13, 2026. To use the universal proxy rules under Rule 14a-19, stockholders soliciting proxies for alternative nominees must also provide the required notice by April 13, 2026. The company will treat stockholder proposals received on or before April 13, 2026 as received a reasonable time before it prints and mails proxy materials for possible inclusion under Rule 14a-8.
Galera Therapeutics, Inc. files its annual report describing a major strategic shift and current risks. The company sold its historical radiotherapy assets, including avasopasem and rucosopasem, to Biossil for a $3.5 million upfront payment plus up to $105.0 million in contingent value rights and milestone opportunities, and Biossil assumed Galera’s royalty obligations to Blackstone.
Galera acquired Nova Pharmaceuticals, adding a pan-NOS inhibitor program now focused on treating aggressive breast cancers such as metaplastic and triple-negative disease. A Phase 1/2 investigator-sponsored trial is underway, funded by an NIH grant, with additional U.S. cancer centers participating. An I-SPY 2 collaboration for triple-negative breast cancer is being planned, contingent on new capital.
As of December 31, 2025, Galera had 3 employees and reported that its cash balance is anticipated to fund operations through the first quarter of 2027. Despite a $151.0 million non-cash gain from extinguishing the Blackstone royalty liability and net income of $149.0 million in 2025, the company carries an accumulated deficit of $307.3 million and warns that its ability to continue as a going concern depends on raising additional funding while it relies heavily on a single, unapproved product candidate.
Galera Therapeutics, Inc. amended the terms of its Series B Non-Voting Convertible Preferred Stock. The company’s board of directors now has the sole discretion to elect to convert, in whole or in part, outstanding shares of this preferred stock into common stock, using the Conversion Ratio defined in the original certificate of designation.
This change was approved both by the board and by unanimous written consent of the holders of the Series B Non-Voting Preferred Stock, and the amendment was filed with the Secretary of State of Delaware as a Certificate of Amendment.
Galera Therapeutics, Inc. entered into a letter agreement with Joel Sussman, its Chief Accounting Officer, Treasurer, Secretary, and a named executive officer, establishing retention-based cash bonus payments tied to timely completion and filing of certain company reporting obligations.
Under the agreement, Mr. Sussman may receive up to $250,000 in total retention bonuses. Any retention bonuses paid will reduce, on a dollar-for-dollar basis, any severance otherwise due to him under his existing employment agreement. If his employment is involuntarily terminated without cause, or he resigns for good reason, any unpaid retention bonus will be paid regardless of whether the original conditions are met.
Galera Therapeutics, Inc. (GRTX) president and CEO J. Mel Sorensen, who is also a director, reported an open market sale of company stock. On 11/20/2025, he sold 70,000 shares of common stock at a weighted average price of $0.0201 per share, with individual trades executed between $0.02 and $0.0201. After this transaction, he beneficially owned 195,029 shares of Galera Therapeutics common stock in direct ownership.
GRTX has a Form 144 notice indicating that an affiliate plans to sell up to 70,000 shares of common stock through Raymond James & Associates on the OTC Markets, with an approximate sale date of 11/20/2025 and an aggregate market value of 1400.00. The table lists 75,462,390 shares of the issuer’s stock as outstanding, providing context for the planned sale size. The seller originally acquired 217,015 common shares on 03/06/2021 via a stock option exercise paid in cash. By signing the notice, the seller represents that they are not aware of any material adverse, non‑public information about the issuer’s current or prospective operations.
Galera Therapeutics (OTCQB:GRTX) reported a smaller quarterly loss and a strategic reset. For the quarter ended September 30, 2025, net loss was $1.4 million versus $5.6 million a year ago as operating expenses fell sharply; research and development was $0.1 million and general and administrative was $1.3 million.
Cash and cash equivalents were $4.5 million, with total assets of $5.0 million and a stockholders’ deficit of $149.2 million. A royalty purchase liability of $151.0 million remained on the balance sheet at quarter‑end, and was subsequently assigned to Biossil alongside the sale of the company’s dismutase mimetic assets for $3.5 million in October 2025. Management states that existing cash plus the $3.5 million will fund limited operations for at least twelve months from issuance.
The business has shifted to a pan‑NOS inhibitor program for difficult breast cancers. An investigator‑sponsored Phase 1/2 study at Houston Methodist is funded by an NIH grant, and a second TNBC trial is being planned with the I‑SPY 2 consortium, subject to additional capital. In December 2024, Galera acquired Nova Pharmaceuticals and issued 119,318 Series B non‑voting convertible preferred shares (each convertible into 1,000 common shares if approved), and completed a $2.9 million private placement at $0.065 per share or pre‑funded warrant. Common shares outstanding were 75,462,390 as of November 12, 2025.
Galera Therapeutics (GRTX) reported that Blackstone executed a notice of assignment acknowledging Galera’s assignment of the Amended and Restated Purchase and Sale Agreement to Biossil Inc. and agreeing to look solely to Biossil for all obligations of the “Seller” under that agreement.
This step follows Galera’s Asset Purchase and Sale Agreement under which it sold all of its dismutase mimetic assets, including avasopasem (GC4419) and rucosopasem (GC4711), to Biossil, with Biossil assuming liabilities related to those assets. The notice of assignment was executed after the transaction and is filed as Exhibit 10.1.
Galera Therapeutics (GRTX) agreed to sell its avasopasem (GC4419), rucosopasem (GC4711), and other dismutase mimetic assets to Biossil Inc. under an Asset Purchase and Sale Agreement, as amended.
The purchase price includes an upfront payment of $3,500,000 and potential future regulatory milestones, commercial milestones, and contingent value rights of up to $105,000,000 in aggregate. Biossil also agreed to assume all further rights and obligations of Galera under the Amended and Restated Purchase and Sale Agreement dated November 14, 2018, with Clarus IV Galera Royalty AIV, L.P., which is affiliated with Blackstone Life Sciences.
The agreement includes customary representations, warranties, and covenants, with certain confidentiality, indemnification, and payment provisions surviving closing. Galera plans to file the full agreement as an exhibit to its next Form 10-Q.